BTD in hand, Exelixis speeds cabo application to FDA

Just weeks after announcing promising trial data, South San Francisco-based Exelixis ($EXEL) says that the FDA has provided its breakthrough therapy designation for cabozantinib (approved as Cometriq) as a second-line treatment for kidney cancer. CEO Michael M. Morrissey says the BTD--designed to accelerate discussions with regulators--sets the stage for moving up its marketing application for renal cell carcinoma to sometime later this year. Exelixis posted positive progression-free survival data in late July. Release

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.